Peters et al reviewed 9 cases of euglycemic DKA, 7 in T1DM and 2 in T2DM patients.9 In the T1DM group, 4 had recurrences of euDKA upon rechallenge with the SGLT2 inhibitor and one had persistent ketonuria 48 hours after discontinuation of canagliflozin. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.